Pilot study of low-dose interleukin-2, pegylated interferon-α2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection

Journal of Infectious Diseases

Volumn 191, Issue 5, 2005, Pages 686-693

  Glesby, Marshall J ^a   Bassett, Roland ^c   Alston Smith, Beverly ^f   Fichtenbaum, Carl ^d   Jacobson, Elizabeth L ^a   Brass, Clifford ^e   Owens, Susan ^b   Sulkowski, Mark ^g   Race, Elizabeth M ^h   Sherman, Kenneth E ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ERYTHROPOIETIN; PEGINTERFERON ALPHA2B; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; FATIGUE; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALAISE; MALE; NAUSEA; NEUTROPENIA; PAIN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VOMITING;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MIDDLE AGED; PATIENT DROPOUTS; PILOT PROJECTS; RIBAVIRIN; T-LYMPHOCYTE SUBSETS;

EID: 13944251642     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427812     Document Type: Article

References (28)

1. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
2. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.
3. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2909-13.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
5. Fried MW, Shiffinan ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
6. Lechmann M, Ihlenfeldt HG, Braunschweiger I, et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 1996; 24:790-5.
7. Hiroishi K, Kita H, Kojima M, et al. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. Hepatology 1997; 25:705-12.
8. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994; 84:1020-3.
9. Lauer GM, Nguyen TN, Day CL, et al. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol 2002; 76:2817-26.
10. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon-α for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23:585-91.
11. + cell count. Infection 1998; 26:16-9.
12. Jacobson EL, Pilaro F, Smith KA. Rational interleukin-2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996; 93:10405-10.
13. Lalezari JP, Beal JA, Ruane PJ, et al. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial. HIV Clin Trials 2000; 1:1-15.
14. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
15. Perez-Olmeda M, Soriano V, Asensi V, et al. Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. AIDS Res Hum Retroviruses 2003; 19:1083-9.
16. Levy Y, Durier C, Krzysiek R, et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003; 17:343-51.
17. + lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis 2003; 187:320-5.
18. + T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J Acquir Immune Defic Syndr 2004; 36:576-87.
19. Emery S, Abrams DI, Cooper DA, et al. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002; 23:198-220.
20. Pardo M, Castillo I, Oliva H, et al. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology 1997; 26:1318-21.
21. Thibault V, Delaugerre C, Calvez V, Costagliola D, Tubiana R, Katlama C. Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial. Hepatology 2002; 35:238-9.
22. Valdez H, Metcalf JA, Gripshover BM, Jacobson JM, Mitsuyasu R, Lederman MM. Effect of IL-2 therapy on plasma hepatitis C virus-RNA levels in HIV/hepatitis C virus co-infected patients. AIDS 2001; 15:661-2.
23. Uberti-Foppa C, De Bona A, Morsica G, et al. Recombinant interleukin-2 for treatment of HIV reduces hepatitis C viral load in coinfected patients [letter]. AIDS 1999; 13:140-1.
24. Schlaak JF, Schramm C, Radecke K, zum Buschenfelde KH, Gerken G. Sustained suppression of HCV replication and inflammatory activity after interleukin-2 therapy in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2002; 29:145-8.
25. Bellentani S, Podda M, Tiribelli C, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993; 19:459-64.
26. Barreiros AP, Schlaak JF, Gerken G, Galle PR, Lohr HF. Interleukin-2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin. Eur J Clin Invest 2003; 33:628-9.
27. Davey RT Jr, Murphy RL, Graziano FM, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy, a randomized controlled trial. JAMA 2000; 284:183-9.
28. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335:1350-6.